se of Curcumin to Reduce ulcers in Gut in patients undergoing Autologous Bone Marrow Transplant

Phase 3

• Conditions: Health Condition 1: K123- Oral mucositis (ulcerative)Health Condition 2: D70-D77- Other disorders of blood and blood-forming organs

• Registration Number: CTRI/2018/09/015846
• Lead Sponsor: The Terry Fox Research Institute

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 24 November 2021

Recruitment & Eligibility

• Status: Open to Recruitment
• Sex: Not specified
• Target Recruitment: 0

Inclusion Criteria

Male or female patients 18 years and above Patients who give written informed consent

Patients with performance status â?? 0,1 or 2 (ECOG scale)

Patients requiring autologous transplant for any malignant disease with any of the following high dose chemotherapy regimens

Melphalan- 200 mg/m2 or more (MEL-200 mg/m2)

Busulfan and Melphalan (BuMEL)

Carmustine (BCNU), Etoposide, Cytosine Arabinoside and Melphalan ( BEAM)

Patients who have creatinine clearance > 50 ml/min

Patients with serum bilirubin levels < 2mg/dl. and serum liver enzymes (ALT or AST or both) lesser than 5 times the upper limit of normal value

Exclusion Criteria

Patients who are on NSAIDs, aspirin, antioxidants or systemic steroids for more than 3 months and the last dose taken within the last one week.

Patients being treated for active infection at the time of starting high dose chemotherapy.

Study & Design

• Study Type: Interventional
• Study Design: Not specified